Novo Nordisk Aktie
WKN: 866931 / ISIN: US6701002056
14.08.2024 12:00:00
|
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
It's not often that a biotech wins when a big pharma stumbles, but Madrigal Pharmaceuticals (NASDAQ: MDGL) is now in a better place than before because of a setback at Danish drug giant Novo Nordisk (NYSE: NVO). The two cardiometabolic drug developers will avoid direct competition for the time being, and now, any head-to-head match up in the future could favor Madrigal a bit more than before.But is the biotech still a buy? Let's clarify the question by looking at what just happened and why it matters.In its second-quarter earnings update for investors, Novo Nordisk disclosed a surprising failure. One of its programs, a unique investigational therapy for metabolic-associated steatohepatitis (MASH, formerly known as NASH), would be terminated immediately. The corresponding phase 1 clinical trial has already been halted well before its completion, and, by the looks of it, there are not any plans to try to revive the program at a later date.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordisk (spons. ADRs)mehr Nachrichten
Analysen zu Novo Nordisk (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Madrigal Pharmaceuticals Inc. | 295,60 | -0,40% |
|
Novo Nordisk (spons. ADRs) | 62,40 | -1,27% |
|